OPDC Collaborators

For more information on collaborating with OPDC please visit our collaboration page

Current Collaborations


The University of Oxford is the academic lead institution for StemBANCC (www.stembancc.org). This 5-year research programme funded by the EU Innovative Medicines Initiative (IMI) involving academic and industry partners across 11 countries with the objective of developing human induced pluripotent stem cells as a platform for drug discovery. 

Richard Wade-Martins leads Work Package 8 (WP8: Central Nervous System: Neurodegenerative and Neurodysfunctional Diseases), with the aim of providing disease-relevant, human in vitro systems in neurons and glia derived from iPSC generated from well-characterised patients with neurodegenerative and neurodysfunctional disorders.

The StemBANCC consortium is an academic-industry partnership that will provide well characterized human induced pluripotent stem cell (iPSC) lines in an accessible and sustainable bio-bank across a range of diseases. StemBANCC will support collection of skin biopsies from Parkinson's patients in the OPDC cohort.


The MRC Dementias Platform UK (DPUK) is a multi-million pound public-private partnership, developed and led by the Medical Research Council, to accelerate progress in, and open up, dementias research. The DPUK’s aims are early detection, improved treatment and ultimately, prevention, of dementias.

Richard Wade-Martins will play a key role in the Stem Cell Network within DPUK which will comprise co-ordinated programmes for the immortalisation of selected cell lines, high-throughput genome editing, and detailed cell phenotyping.  Simon Lovestone and Clare MacKay play leading roles in DPUK and will lead on the DPUK national informatics program, to include imaging.


OPDC's Michele Hu will work on the JPND project "Harmonization of biomarker assessment in longitudinal cohort studies in Parkinson’s disease". In this working group representatives of numerous European longitudinal cohort studies in different phases of Parkinson's and epidemiologists will work on a consensus for single and combinations of predictive and progression markers and standardization of assessments for Parkinson’s.


ProBAND is a large, nationwide, multi-centre cohort of people with Parkinson's supported by Parkinson's UK working in close collaboration with the OPDC.  We will use genetic modelling of extreme clinical phenotypes in OPDC and PRoBaND cohorts to increase power to detect variants predisposing to Parkinson's occurrence and subtype.

No Tremor

NoTremor -Virtual, Physiological and Computational Neuromuscular Models for the Predictive Treatment of Parkinson’s Disease- is a EU FP7-ICT funded project. It aims to provide patient specific computational models of the coupled brain and neuromuscular systems that will be subsequently used to improve the quality of analysis, prediction and progression of Parkinson’s. 

The OPDC has formed a strategic alliance with the National Centre of Excellence in Research on Parkinson’s disease, a joint research program by all biomedical research partners in Luxembourg led by Rejko Kruger. The research focuses on improving the diagnosis and stratification of Parkinson's disease by combining detailed clinical and molecular data of patients to develop novel disease biomarker signatures. An important component of the Centre will be a Parkinson's patient cohort as a nationwide effort that will establish the core of a future PD-registry in Luxembourg.

The OPDC is one of the international partners working with this study; other partners are the DeNoPa study led by Prof. Britt Mollenhauer (Paracelsus Elena Hospital in Kassel) and the TREND and PMPP cohorts led by Prof. Daniela Berg (Hertie Institute for Clinical Brain Research).

Oxford has one of three flagship Drug Discovry Institutes funded by Alzheimer’s Research UK. The team at Oxford is developing multiple projects to identify new therapeutic targets in Alzheimer's, Parkinson's and motor neuron disease. Professor Richard Wade-Martins is the Parkinson’s research lead on this £10M project.